| Literature DB >> 35813721 |
Taehwa Kim1, Hye Ju Yeo1, Jin Ho Jang1, Dohyung Kim2,3, Doosoo Jeon1,3, Yun Seong Kim1,3, Woo Hyun Cho1,3.
Abstract
Background: The number of lung transplantation procedures is rapidly increasing worldwide. Little is known about the effect of perioperative respiratory microbial colonization on pneumonia during lung transplantation. We evaluated the microbiome composition and incidence of early pneumonia in patients undergoing lung transplantation. We investigated factors related to post-transplant pneumonia (PTP) after lung transplantation.Entities:
Keywords: Pneumonia; colonization; lung transplantation; multidrug-resistant (MDR) bacteria
Year: 2022 PMID: 35813721 PMCID: PMC9264098 DOI: 10.21037/jtd-21-1724
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 3.005
Baseline characteristics and outcomes of 1-year survivors and non-survivors
| Variables | Total (N=76) | Survivor (N=52) | Non-survivor (N=24) | P |
|---|---|---|---|---|
| Donor variables | ||||
| Age (years) | 40.1±12.6 | 39.7±12.3 | 41.1±13.5 | 0.665 |
| PF ratio | 426.6±120.0 | 434.1±109.0 | 407.5±145.3 | 0.403 |
| TLC DR ratio | 1.0±0.4 | 1.1±0.1 | 0.9±0.7 | 0.286 |
| Recipient variables | ||||
| Age (years) | 56.6±10.3 | 55.2±10.8 | 59.7±8.0 | 0.052 |
| Sex (M) | 48 (63.2) | 32 (61.5) | 16 (66.7) | 0.667 |
| BMI | 21.7±4.3 | 21.2±4.6 | 22.6±3.5 | 0.187 |
| Aetiology | 0.470 | |||
| DILD | 43 (56.6) | 29 (55.8) | 14 (58.3) | |
| COPD | 7 (9.2) | 6 (11.5) | 1 (4.2) | |
| Post-ARDS lung fibrosis | 13 (17.1) | 8 (15.4) | 5 (20.8) | |
| Pulmonary graft versus host disease | 7 (9.2) | 6 (11.5) | 1 (4.2) | |
| Bronchiectasis | 1 (1.3) | 0 | 1 (4.2) | |
| Others | 5 (6.6) | 3 (5.8) | 2 (8.3) | |
| BTT | 60 (78.9) | 39 (75.0) | 21 (87.5) | 0.214 |
| *Adequacy of prophylactic antibiotics | 21 (27.6) | 13 (25.0) | 8 (33.3) | 0.450 |
| Preoperative sputum colonisation | ||||
| Donor | 34 (44.7) | 24 (46.2) | 10 (41.7) | 0.715 |
| Recipient | 28 (36.8) | 16 (30.8) | 12 (50.0) | 0.106 |
| Clinical outcome | ||||
| Early PTP | 37 (48.7) | 20 (38.5) | 17 (70.8) | 0.009 |
| Postoperative VFD within 28 days | 14.5±9.8 | 15.4±9.7 | 12.6±9.9 | 0.264 |
| Postoperative ICU stay (days) | 20.7±17.6 | 15.3±12.6 | 32.3±21.4 | 0.001 |
Data is presented as mean ± standard deviations or number (%). *, adequacy of prophylactic antibiotics. Appropriate antimicrobial treatment is defined as the use of agents with in vitro activity against the etiologic pathogens based on our hospital’s diagnostic laboratory results (18). PF ratio, PaO2/FiO2 ratio; TLC DR ratio, total lung capacity donor/recipient ratio; BMI, body mass index; DILD, diffuse interstitial lung disease; COPD, chronic obstructive pulmonary disease; ARDS, acute respiratory distress syndrome; BTT, bridge to transplantation; PTP, post-transplant pneumonia; VFD, ventilator-free day, defined as days alive and free from mechanical ventilation; ICU, intensive care unit.
Figure 1Perioperative respiratory culture results from the overall population (n=76).
Cox proportional hazard model for 1-year mortality
| Variables | Univariate | Multivariate | |||
|---|---|---|---|---|---|
| HR (CI) | P | HR (CI) | P | ||
| Recipient | |||||
| *Age | 3.523 (1.4–9.2) | 0.010 | 3.954 (1.5–10.3) | 0.005 | |
| BMI | 1.063 (1.0–1.2) | 0.146 | |||
| Preoperative sputum colonization | 1.917 (0.9–4.3) | 0.111 | 2.550 (1.2–5.2) | 0.010 | |
| BTT | 2.010 (0.6–6.7) | 0.258 | |||
| PTP | 3.067 (1.3–7.4) | 0.013 | 3.239 (1.4–7.3) | 0.005 | |
*, age was used as a qualitative variable with a breakpoint 55 yrs. HR, hazard ratio; CI, confidence interval; BMI, body mass index; BTT, bridge to transplantation; PTP, post-transplant pneumonia.
Baseline characteristics and outcomes according to early PTP
| Variables | Total (N=76) | With PTP (N=37) | Without PTP (N=39) | P |
|---|---|---|---|---|
| Donor variables | ||||
| Age | 40.1±12.6 | 40.6±12.3 | 39.6±13.0 | 0.726 |
| PF ratio | 426.6±120.0 | 422.5±145.0 | 430.4±92.7 | 0.784 |
| TLC DR ratio | 1.0±0.4 | 1.0±0.4 | 1.0±0.4 | 0.902 |
| Recipient variables | ||||
| Age | 56.6±10.3 | 55.4±11.9 | 57.8±8.4 | 0.318 |
| Sex (M) | 48 (63.2) | 24 (64.9) | 24 (61.5) | 0.764 |
| BMI | 21.7±4.3 | 22.1±4.2 | 21.3±4.4 | 0.407 |
| Aetiology | 0.828 | |||
| DILD | 43 (56.6) | 21 (56.8) | 22 (56.4) | |
| COPD | 7 (9.2) | 4 (10.8) | 3 (7.7) | |
| Post-ARDS lung fibrosis | 13 (17.1) | 5 (13.5) | 8 (20.5) | |
| Pulmonary graft versus host disease | 7 (9.2) | 4 (10.8) | 3 (7.7) | |
| Bronchiectasis | 1 (1.3) | 1 (2.7) | 0 | |
| Others | 2 (5.4) | 3 (7.7) | ||
| BTT | 60 (78.9) | 30 (81.1) | 30 (76.9) | 0.657 |
| *Adequacy of prophylactic antibiotics | 21 (27.6) | 10 (27.0) | 11 (28.2) | 0.909 |
| Preoperative respiratory colonisation | ||||
| Positive culture in donor | 34 (44.7) | 19 (51.4) | 15 (38.5) | 0.259 |
| Positive culture in recipient | 28 (36.8) | 16 (43.2) | 12 (30.8) | 0.260 |
| **MDR pathogen in recipient | 19 (25.0) | 13 (35.1) | 6 (15.4) | 0.047 |
| Clinical outcome | ||||
| Postoperative ICU stay (days) | 20.7±17.6 | 27.6±20.6 | 14.1±11.0 | 0.001 |
| Postoperative HOS (days) | 63.1±43.7 | 76.0±50.9 | 50.9±31.7 | 0.011 |
| 1-year survival | 52 (68.4) | 20 (54.1) | 32 (82.1) | 0.009 |
Data is presented as mean ± standard deviations or number (%). *, adequacy of prophylactic antibiotics. Appropriate antimicrobial treatment is defined as the use of agents with in vitro activity against the etiologic pathogens based on our hospital diagnostic laboratory results (18); **, MDR pathogen was included methicillin-resistant staphylococcus, carbapenem-resistant Acinetobacter baumannii, and carbapenem-resistant Pseudomonas aeruginosa. PTP, post-transplant pneumonia; PF ratio, PaO2/FiO2 ratio; TLC DR ratio, total lung capacity donor/recipient ratio; BMI, body mass index; DILD, diffuse interstitial lung disease; COPD, chronic obstructive pulmonary disease; ARDS, acute respiratory distress syndrome; BTT, bridge to transplantation; MDR, multidrug resistant; ICU, intensive care unit; HOS, hospital of stay.
Binary logistic regression analysis for risk factors of early postoperative pneumonia
| Variables | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | ||
| Recipient | |||||
| *Age | 0.974 (0.4–2.3) | 0.951 | |||
| Preoperative SC MDR | 2.979 (1.0–9.0) | 0.052 | 3.284 (1.2–8.8) | 0.018 | |
| Donor | |||||
| Preoperative SC MDR | 1.550 (0.5–4.9) | 0.455 | |||
| BTT | 1.286 (0.4–3.9) | 0.657 | |||
| **Appropriateness of prophylactic antibiotics | 0.943 (0.3–2.6) | 0.909 | |||
*, age was used as a qualitative variable with a breakpoint 55 yrs; **, adequacy of prophylactic antibiotics. Appropriate antimicrobial treatment is defined as the use of agents with in vitro activity against the etiologic pathogens based on our hospital diagnostic laboratory results (18). BMI, body mass index; SC, sputum culture; MDR, multidrug resistance; BTT, bridge to transplantation; OR, odds ratio.
Figure 2Post-transplant pneumonia (PTP) was significantly associated with 1-year mortality in patients with lung transplantation. Kaplan-Meier analysis. χ2=6.849, P=0.009.